STIOLTO RESPIMAT Shown To Clinically Improve Disease Conditions In COPD Patients
Boehringer Ingelheim recently announced the completion of the phase IIIb OTEMTO® 1 & 2 trials for their pipeline drug STIOLTO RESPIMAT, and have published the study data online in the Respiratory Medicine journal. The new data reveals that the drug has the potential to improve clinical outcomes in patients with…